Monotherapy with the PD-L1 inhibitor durvalumab was investigated in the HAWK trial and demonstrated antitumor activity with an acceptable safety profile in patients with >25% PD-L1 expressing tumor cells [87]. This evidence concerns the gene CD274 and neoplasm.